TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. - Wikidata - wikimedia - TriplyDB

TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome.

TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome.

http://www.wikidata.org/entity/Q34571799

about

Is the risk of cardiovascular disease altered with anti-inflammatory therapies? Insights from rheumatoid arthritis Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis?Atherosclerosis in psoriatic disease: latest evidence and clinical implications Something old, something new and something very old: drugs for treating type 2 diabetes Adipokines - removing road blocks to obesity and diabetes therapy Adipose tissue in obesity-related inflammation and insulin resistance: cells, cytokines, and chemokines Obesity: An Immunometabolic Perspective Nonalcoholic fatty liver disease - A multisystem disease?Chemerin and adiponectin contribute reciprocally to metabolic syndrome Adipokines in inflammation and metabolic disease Role of T cells in malnutrition and obesity.Transcription of the gene encoding TNF-α is increased by IL-1β in rat and human islets and β-cell lines Nutritional recovery promotes hypothalamic inflammation in rats during adulthood Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease.Inflammatory links between obesity and metabolic disease.Estrogen sulfotransferase is expressed in subcutaneous adipose tissue of obese humans in association with TNF-alpha and SOCS3 Advanced application of porcine intramuscular adipocytes for evaluating anti-adipogenic and anti-inflammatory activities of immunobiotics Hypothalamic inflammation: a double-edged sword to nutritional diseases.Adipokines as drug targets in diabetes and underlying disturbances.Therapeutic approaches to target inflammation in type 2 diabetes LTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes.Deficiency of ACE2 in Bone-Marrow-Derived Cells Increases Expression of TNF-α in Adipose Stromal Cells and Augments Glucose Intolerance in Obese C57BL/6 Mice Inverse Relationship between Serum Lipoxin A4 Level and the Risk of Metabolic Syndrome in a Middle-Aged Chinese Population Inflammatory cause of metabolic syndrome via brain stress and NF-κB.Inflammation as a Link between Obesity and Metabolic Syndrome.Linking inflammation to the brain-liver axis.The Roles of Adipokines, Proinflammatory Cytokines, and Adipose Tissue Macrophages in Obesity-Associated Insulin Resistance in Modest Obesity and Early Metabolic Dysfunction.Treatment-specific changes in circulating adipocytokines: a comparison between tumour necrosis factor blockade and glucocorticoid treatment for rheumatoid arthritis.The inflammation highway: metabolism accelerates inflammatory traffic in obesity.Hyporesponsiveness to the anti-inflammatory action of interleukin-10 in type 2 diabetes The vascular endothelium in diabetes--a therapeutic target?Insulin signalling mechanisms for triacylglycerol storage.Gene silencing in adipose tissue macrophages regulates whole-body metabolism in obese mice.Therapeutic Targets for Management of Periodontitis and Diabetes Adipokines mediate inflammation and insulin resistance Colchicine to decrease NLRP3-activated inflammation and improve obesity-related metabolic dysregulation.Metabolic reprogramming through fatty acid transport protein 1 (FATP1) regulates macrophage inflammatory potential and adipose inflammation.Inflammation during obesity is not all bad: evidence from animal and human studies.Stress in obesity and associated metabolic and cardiovascular disorders.Innate immune activation in obesity.

P2860

Q26746659-2FFB9138-5C28-4BA6-99A5-888D8987A430 Q26767276-CE045989-0D4B-4BF6-9EF2-5CE9D8813671 Q26783501-43DF410A-3BF0-45F3-A986-5652BFB04661 Q26865663-ED2EC20C-0AD7-44B2-B9A0-80A2CC3148F2 Q26995825-6492482C-AB5D-482A-99C1-03BD20B2C30C Q27001148-78090556-F132-495E-B0A1-C7978649ED58 Q28072140-919B36CF-5BBA-4519-ACC3-0D8C7158DE70 Q28079077-E0D67821-601B-41FE-A28D-929237125FDB Q28730639-7F6A7996-913D-49FB-9B8E-4ED3DAC17028 Q29620456-CA933FA9-05F3-4DA6-A91A-D4B20097705E Q34023205-86E2B138-C052-4689-AC9E-A7D1C230A088 Q34146626-6A880D2E-A90D-42C1-9EC2-7F57695E6AFD Q34199264-1037CA2E-B2B4-4EB2-93C2-C668413749A7 Q34444895-67D3F5A2-39A1-458D-BC6C-F132759F37FE Q35015802-E0036D40-3B1E-4950-ABF4-FCBC26021BEA Q35101803-39F0C050-CAAB-462B-98EF-E8E192D411D6 Q35196625-1C826B12-2ECA-4A74-8581-3959D1CF469B Q35318592-C36FE152-325C-48AE-996B-357BFDD718AB Q35415815-546C15B0-F8C2-4323-ADA2-8F30D9358C87 Q35581498-A90BE701-1381-4BBC-A26D-8F7DC876C7DC Q35600641-7BE23663-23AB-4CBF-80C1-87333805BB00 Q35810634-93A9B8ED-029D-41A9-9AB1-095DD41C037D Q35840855-2F078AA5-5BC8-40FF-AD44-1CDC90F5A3F2 Q35857192-92E29DF9-3888-4EAE-9614-71FB912A9138 Q35864675-E60E1451-BA2C-42BB-8885-E4AAE03D8CEE Q35976689-C131F054-A64B-4528-8869-C93376A41E94 Q35996323-31BF5EB3-5FA0-4253-BE8A-1C94B7DDC541 Q36148660-4F2C3D11-B953-4A47-B04E-82F5233A021C Q36174974-EFA16733-D10F-49CD-AC44-31F86F3024F2 Q36588627-30029672-5AE0-4285-AC07-FE6405070C67 Q36673550-E09F193A-4A06-432A-B996-22184AEAC84A Q36838847-262C3880-02A1-4D74-8E3D-5DCBFB766C4E Q36855257-4B82F0F7-33F9-434D-B872-D6EDB8CA2BE4 Q36863273-3E58BE25-E032-4852-B893-3E61FE5E01A4 Q36920864-95D02B88-89C3-434F-B5D4-F9A31CF4AF91 Q36959839-D13A6DFC-4540-4D86-9AD5-D12FE031AE47 Q37040183-8CEB40FF-2413-4F0F-85F6-F54C5C9CF0B7 Q37174503-EC34A9CC-CDB4-4BCB-BC79-231500174E06 Q37288068-16FCCA61-82F3-4C30-BEF9-34A545995785 Q37466096-1AD6467A-FAFE-4482-A1FE-9E457CCEF196

P2860

TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome.

http://www.wikidata.org/entity/Q34571799

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

TNF-alpha antagonism with etan ...... res of the metabolic syndrome.

@ast

TNF-alpha antagonism with etan ...... res of the metabolic syndrome.

@en

TNF-alpha antagonism with etan ...... res of the metabolic syndrome.

@nl

type

label

TNF-alpha antagonism with etan ...... res of the metabolic syndrome.

@ast

TNF-alpha antagonism with etan ...... res of the metabolic syndrome.

@en

TNF-alpha antagonism with etan ...... res of the metabolic syndrome.

@nl

prefLabel

TNF-alpha antagonism with etan ...... res of the metabolic syndrome.

@ast

TNF-alpha antagonism with etan ...... res of the metabolic syndrome.

@en

TNF-alpha antagonism with etan ...... res of the metabolic syndrome.

@nl

P1433

Q34571799-649AF09B-8BA6-4E94-B6A0-F2D394ECCB51

P1476

Q34571799-1CF512E0-F76E-4DCF-9DB2-7A18CC6D2A2E

P2093

Q34571799-30408737-1DCD-482B-B8FC-B6A6AC7B3CD5

Q34571799-44463CB7-5504-432A-9FA3-84AC4963A5E4

Q34571799-517B0054-5E20-49FC-8C9F-1FF1C5FBB825

Q34571799-6079F35B-58C4-434E-9A8A-CA3B2ABF6AD6

Q34571799-7A903C3D-1585-4BAE-B89A-8710BFA47C74

Q34571799-C8447D81-5624-4007-A0EE-4D57624B0F37

Q34571799-D96AEBC7-2ECB-47AB-A57A-8E3559D5E988

Q34571799-DBAFED12-EC13-42A3-BDF3-0A54DBEC00BB

Q34571799-F4DC3AD7-6A3F-4D07-895B-53D402771457

P2860

Q34571799-07E236BB-B8EF-464B-B13E-BEF2F82C641C

Q34571799-1E82DF6C-60AE-41FD-AD1A-12D3CC4C62F8

Q34571799-24A9C5C2-D6C3-40CB-BE56-E662006E597D

Q34571799-448419AB-9D9F-4D88-8F35-915F9262A287

Q34571799-585E374A-CB15-4B49-9094-06550FC3F2F8

Q34571799-65C8E811-4DAC-4802-9D3E-67D1B45454D7

Q34571799-6E649969-B054-469B-8AE4-822E456169B3

Q34571799-8967C2F6-55BA-40CC-843A-0D4A1115202C

Q34571799-8D3B69BB-C303-400A-B09F-6055465D0F6C

Q34571799-9057087E-1F31-41CD-8993-E61815885CFC

P304

Q34571799-F9087A64-BA44-4834-8E7D-DFC8539E1FB4

P31

Q34571799-6A7FDDC1-0DC7-4EE7-B054-31BCFFC3E855

P356

Q34571799-E5985E87-38BA-4982-B4F6-791EAA52FCAA

P407

Q34571799-075911EC-4751-4C4F-AD35-CBBE240A2F25

P433

Q34571799-A09932BB-0F7D-4C9C-9732-BD0752BB8765

P478

Q34571799-AEB926E5-C29C-46F2-ADD2-CFEA9D3E640A

P577

Q34571799-85D21F58-2F0B-4D2F-95B2-9BD752756DD0

P5875

Q34571799-88A8BB87-231F-4A0C-AACE-D8B3FD812E40

P698

Q34571799-D54F2FDA-CEC3-4141-8D49-820E2570FCE4

P921

Q34571799-0d5456f5-1dde-4cfe-b9e0-4d2ad20131a5

Q34571799-11E7E5E3-FFEC-4463-9C1C-5ADA4C488B00

Q34571799-A9453B1B-9EE5-40B2-860C-868AADBB8098

Q34571799-E955A23E-8CFA-46FC-BB2F-781F9112A957

P932

Q34571799-496147BC-09FB-4A72-B1A1-02D0F77DBF84

P356

P1433

The Journal of Clinical Endocrinology and Metabolism

P1476

TNF-alpha antagonism with etan ...... res of the metabolic syndrome.

@en

P2093

Hang Lee

http://www.w3.org/2001/XMLSchema#string

Hideo Makimura

http://www.w3.org/2001/XMLSchema#string

Markella V Zanni

http://www.w3.org/2001/XMLSchema#string

Rexford S Ahima

http://www.w3.org/2001/XMLSchema#string

Sarah Rasheed

http://www.w3.org/2001/XMLSchema#string

Steven K Grinspoon

http://www.w3.org/2001/XMLSchema#string

Stine Johnsen

http://www.w3.org/2001/XMLSchema#string

Takara L Stanley

http://www.w3.org/2001/XMLSchema#string

Victor K Khor

http://www.w3.org/2001/XMLSchema#string

P2860

Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance

Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance.

Effects of etanercept in patients with the metabolic syndrome.

Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus

Increase in plasma endotoxin concentrations and the expression of Toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: implications for insulin resistance.

SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice.

Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events.

Assessment of abdominal fat content by computed tomography.

Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis.

Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss.

P304

E146-50

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/JC.2010-1170

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

96

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47675720

http://www.w3.org/2001/XMLSchema#string

P698

21047923

http://www.w3.org/2001/XMLSchema#string

P921

metabolic syndrome

P932

3038481

http://www.w3.org/2001/XMLSchema#string